Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation

Medical Science Monitor

Volumn 13, Issue 12, 2007, Pages

  Das, Undurti N ^a  

^a UND LIFE SCIENCES   (United States)

Author keywords

Acetylcholine; Acetylcholinesterase; Alzheimer's disease; Butyrylcholinesterase; Coronary heart disease; Hypertension; Inflammation; Insulin resistance; Interleukins; Tumor necrosis factor; Type 2 diabetes mellitus

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLINESTERASE; DOPAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPID PEROXIDASE; MACROPHAGE MIGRATION INHIBITION FACTOR; NITRIC OXIDE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NEUROTRANSMISSION; NONHUMAN; OBESITY; REVIEW; STREPTOZOCIN DIABETES;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BUTYRYLCHOLINESTERASE; CYTOKINES; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; NF-KAPPA B;

EID: 37249057800     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Das UN: Clinical laboratory tools to diagnose inflammation. Adv Clin Chemistry, 2006; 41: 189-229
2. Das UN: Is metabolic syndrome X an inflammatory condition? Exp Biol Med, 2002; 227: 989-97
3. Ford ES: The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis, 2003; 168: 351-58
4. Luc G, Bard J-M, Juhan-Vague I et al: C-reactive protein, interleukins-6, and fibrinogen as predictors of coronary heart disease. The PRIME study. Arterioscler Thromb Vasc Biol, 2003; 23: 1255-61
5. Ridker PM, Cushman M, Stampfer MJ et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997; 336: 973-79
6. Engstrom G, Hedblad B, Stavenow L et al: Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 2003; 52: 2097-101
7. Das UN: Is obesity an inflammatory condition? Nutrition, 2001; 17: 953-66
8. Ridker PM, Rifai N, Pfeffer M et al: Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation, 2000; 101: 2149-53
9. Das UN: Hypertension as a low-grade systemic inflammatory condition that has its origins in the perinatal period. J Assoc Physicians India, 2006; 54: 133-42
10. Luc G, Bard J-M, Juhan-Vague I et al: C-reactive protein, interleukins-6, and fibrinogen as predictors of coronary heart disease. The PRIME study. Arterioscler Thromb Vasc Biol 2003; 23: 1255-61
11. Das UN: Essential fatty acids: Biochemistry, physiology, and pathology. Biotechnology J, 2006; 1: 420-39
12. Kumar KV, Das UN: Are free radicals involved in the pathobiology of human essential hypertension? Free Rad Res Commun, 1993; 19: 59-66
13. Mohan IK, Das UN: Oxidant stress, anti-oxidants and nitric oxide in noninsulin dependent diabetes mellitus. Med Sci Res, 1997; 25: 55-57
14. Das UN: Essential fatty acid metabolism in patients with essential hypertension, diabetes mellitus, and coronary heart disease. Prostaglandins Leukot Essen Fatty Acids, 1995; 52: 387-91
15. Cacabelos R, Barquero M, Garcia P et al: Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Methods Find Exp Clin Pharmacol, 1991; 13: 455-58
16. Fillit H, Ding WH, Buee L et al: Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett, 1991; 129: 318-20
17. Chao CC, Hu S, Frey WH II et al: Transforming growth factor beta in Alzheimer's disease. Clin Diagn Lab Immunol, 1994; 1: 109-10
18. Donnelly RJ, Friedhoff AJ, Beer B et al: Interleukin-1 stimulates the beta-amyloid precursor protein promoter. Cell Mol Neurobiol, 1990; 10: 485-95
19. Blume AJ, Vitek MP: Focusing on IL-1-promotion of beta-amyloid precursor protein synthesis as an early event in Alzheimer's disease. Neurobiol Aging, 1989; 10: 406-8
20. Tobinick E, Gross H, Weinberger A, Cohen H: TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed, 2006; 8: 25
21. Rosenberg PB: Cytokine inhibition for treatment of Alzheimer's disease. Med Gen Med, 2006; 8: 24
22. Kaplay SS: Acetylcholinesterase and butyrylcholinesterase of developing human brain. Biol Neonate, 1976; 28: 65-73
23. Jope RS, Walter-Ryan WG, Alarcon RD, Lally KM: Cholinergic processes in blood samples from patients with major psychiatric disorders. Biol Psychiatry, 1985; 20: 1258-66
24. Perry E, Perry R, Blessed G, Tomlinson B: Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol, 1978; 4: 273-77
25. Geula C, Mesulam MM: Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord, 1995; 9(Suppl.2): 23-28
26. Lahiri D, Farlow M, Sambamurti K et al: A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets, 2003; 4: 97-112
27. Soreq H, Seidman S: Acetylcholinesterase - new roles for an old actor. Nat Rev Neurosci, 2001; 2: 294-302
28. Taylor P: In The Pharmacological Basis of Therapeutics. Hardman J, Limbird J, Molinoff P et al (eds.). McGraw-Hill, New York, 1996; 161-76
29. Yu Q, Holloway H, Utsuki T et al: Synthesis of novel phenserine-based- selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J Med Chem, 1999; 42: 1855-61
30. Li B, Stribley J, Ticu A et al: Abundant tissue butyrylcholinesterase and its possible function In the acetylcholinesterase knockout mouse. J Neurochem, 2000; 75: 1320-31
31. Darvesh S, Hopkins D, Geula C: Neurobiology of butyrylcholinesterase. Nat Rev Neurobiol, 2003; 4: 131-38
32. Silver A. The Biology of Cholinesterases, Elsevier/Agricultural Reserach Council Institute. New York, 1974; 426-47
33. Mesulam M, Guillozet A, Shaw P et al: Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience, 2002; 110: 627-39
34. Arendt T, Bruckner M, Lange M, Bigl V: Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int, 1992; 21: 381-96
35. Giacobini E: Cholinesterases: new roles in brain function and in Alzheimer's disease. Int J Geriatr Psychiatry, 2003; 18(Suppl.1): S1-5
36. Graybiel A, Ragsdale C Jr: Pseudocholinesterase staining in the primary visual pathway of the macaque monkey. Nature, 1982; 299: 439-42
37. Darvesh S, Grantham D, Hopkins D: Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol, 1998; 393: 374-90
38. Giacobini E, Spiegel R, Enz A et al: Inhibition of acetyl- and butyrylcholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neurol Trans, 2002; 109: 1053-55
39. Guillozet A, Smiley J, Mash D, Mesulam M: Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol, 1997; 42: 909-18
40. Greig NH, Utsuki T, Ingram DK et al: Selective butyrylcholinsterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer's b-amyloid peptide in rodent. Proc Natl Acad Sci USA, 2005; 102: 17213-18
41. Godfrey DA, Matschinsky FM: Enzymes of the cholinergic system in islets of Langerhans. J Histochem Cytochem, 1975; 23: 645-51
42. Abbott CA, Mackness MI, Kumar S et al: Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clin Sci (Lond), 1993; 85: 77-81
43. Sanchez-Chavez G, Salceda R: Effect of streptozotocin-induced diabetes on activities of cholinesterases in the rat retina. IUBMB Life, 2000; 49: 283-87
44. Sanchez-Chavez G, Salceda R: Acetyl- and butyrylcholinesterase molecular forms in normal and streptozotocin-diabetic rat retinal pigment epithelium. Neurochem Int, 2001; 39: 209-15
45. Sanchez-Chavez G, Salceda R: Acetyl- and butyrylcholinesterase in normal and diabetic rat retina. Neurochem Res, 2001; 26: 153-59
46. Hashim Y, Shepherd D, Wiltshire S et al: Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects. Diabetologia, 2001; 44: 2227-30
47. Dave KR, Katyare SS: Effect of alloxan-induced diabetes on serum and cardiac butyrylcholinesterases in the rat. J Endocrinol, 2002; 175: 241-50
48. Alcantara VM, Chautard-Freire-Maia EA, Scartezini M et al: Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand J Clin Lab Invest, 2002; 62: 399-404
49. Mahmoud FF, Haines DD, Abdul HT et al: Butyrylcholinesterase activity in gestational diabetes: correlation with lymphocyte subpopulations in peripheral blood. Am J Reprod Immunol, 2006; 56: 185-92
50. Sridhar GR, Nirmala G, Apparao A et al: Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach. Lipids Health Dis, 2005; 4: 18
51. Sreedhar G, Thota H, Allam AR et al: Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection? Lipids Health Dis, 2006; 5: 28
52. Calderon-Margalit R, Adler B, Abramson JH et al: Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem, 2006; 52: 845-52
53. Alcnatara VM, Oliveira LC, Rea RR et al: Butyrylcholinesterase activity and metabolic syndrome in obese patients. Clin Chem Lab Med, 2005; 43: 285-88
54. Randell EW, Mathews MS, Zhang H et al: Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Chem, 2005; 38: 799-805
55. Valle A, O'Connor DT, Taylor P et al: Butyrylcholinesterase: association with the metabolic syndrome and identification of 2 gene loci affecting activity. Clin Chem, 2006; 52: 1014-20
56. Berchtold NC, Kesslak JP, Cotman CW: Hippocampal brain-derived neurotrophic factor gene regulation by exercise and the medial septum. J Neurosci Res, 2002; 68: 511-21
57. Johnson LR, Rush JW, Turk JR et al: Short-term exercise training increases ACh-induced relaxation and eNOS protein in porcine pulmonary arteries. J Appl Physiol, 2001; 90: 1102-10
58. Hambrecht R, Wolf A, Gielen S et al: Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med, 2000; 342: 454-60
59. Borovikova LV, Ivanova S, Zhang M et al: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature, 2000; 405: 458-62
60. Das UN, Das UN: Exercise and inflammation. Eur Heart J, 2006; 27: 1385-86
61. Das UN: Anti-inflammatory nature of exercise. Nutrition, 2004; 20: 323-26
62. Pavlov VA, Tracey KJ: Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem Soc Trans, 2006; 34(Pt 6): 1037-40
63. Pavlov VA, Tracey KJ: Neural regulators of innate immune responses and inflammation. Cell Mol Life Sci, 2004; 61: 2322-31
64. Wang H, Liao H, Ochani M et al: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med, 2004; 10: 1216-21
65. Czura CJ, Friedman SG, Tracey KJ: Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway. J Endotoxin Res, 2003; 9: 409-13
66. Blaise GA, Stewart DJ, Guerard MJ: Acetylcholine stimulates release of endothelium-derived relaxing factor in coronary arteries of human organ donors. Can J Cardiol, 1993; 9: 813-20
67. Andriantsitohaina R, Surprenant A: Acetylcholine released from guinea-pig submucosal neurones dilates arterioles by releasing nitric oxide from endothelium. J Physiol 1992; 453: 493-502
68. Ramirez MJ, Cenarruzabeitia E, Lasheras B, Del Rio J: 5-HT2 receptor regulation of acetylcholine release induced by dopaminergic stimulation in rat striatal slices. Brain Res, 1997; 757: 17-23
69. Das UN: Is type 2 diabetes mellitus a disorder of the brain? Nutrition, 2002; 18: 667-72
70. Das UN: Metabolic syndrome X is a low-grade systemic inflammatory condition with its origins in the perinatal period. Current Nutrition Food Sci, in press
71. Das UN: A defect in the activity of ?6 and ?5 desaturases may be a factor in the initiation and progression of atherosclerosis. Prostaglandins Leukot Essen Fatty Acids 2007; 76: 251-68
72. Das UN: Is depression a low-grade systemic inflammatory condition? Am J Clin Nutr 2007; 85: 1665-66
73. Das UN: Can perinatal supplementation of long-chain polyunsaturated fatty acids prevents schizophrenia in adult life? Med Sci Monit, 2004; 10(12): HY33-37
74. Das UN: Can perinatal supplementation of long-chain polyunsaturated fatty acids prevent atopy, bronchial asthma and other inflammatory conditions? Med Sci Monit, 2006; 12(6): RA99-111
75. Das UN: A radical approach to cancer. Med Sci Monit, 2002; 8(4): RA79-92
76. Das UN: Perinatal supplementation of long-chain polyunsaturated fatty acids, immune response, and adult diseases. Med Sci Monit, 2004; 10(5): HY19-25